- Home
- RYDE vs CANF Comparison
RYDE vs CANF Comparison
Compare RYDE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- CANF
- Stock Information
- Founded
- RYDE 2014
- CANF 1994
- Country
- RYDE Singapore
- CANF Israel
- Employees
- RYDE N/A
- CANF N/A
- Industry
- RYDE
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- CANF Health Care
- Exchange
- RYDE NYSE
- CANF Nasdaq
- Market Cap
- RYDE 5.2M
- CANF 14.8M
- IPO Year
- RYDE 2024
- CANF N/A
- Fundamental
- Price
- RYDE $0.31
- CANF $1.04
- Analyst Decision
- RYDE
- CANF Strong Buy
- Analyst Count
- RYDE 0
- CANF 2
- Target Price
- RYDE N/A
- CANF $14.00
- AVG Volume (30 Days)
- RYDE 29.3M
- CANF 138.7K
- Earning Date
- RYDE 05-02-2025
- CANF 04-14-2025
- Dividend Yield
- RYDE N/A
- CANF N/A
- EPS Growth
- RYDE N/A
- CANF N/A
- EPS
- RYDE N/A
- CANF N/A
- Revenue
- RYDE $6,557,978.00
- CANF $674,000.00
- Revenue This Year
- RYDE $21.13
- CANF $461.72
- Revenue Next Year
- RYDE $13.43
- CANF N/A
- P/E Ratio
- RYDE N/A
- CANF N/A
- Revenue Growth
- RYDE 3.27
- CANF N/A
- 52 Week Low
- RYDE $0.16
- CANF $0.98
- 52 Week High
- RYDE $22.49
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- CANF 44.04
- Support Level
- RYDE N/A
- CANF $1.01
- Resistance Level
- RYDE N/A
- CANF $1.09
- Average True Range (ATR)
- RYDE 0.00
- CANF 0.05
- MACD
- RYDE 0.00
- CANF 0.00
- Stochastic Oscillator
- RYDE 0.00
- CANF 33.28
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).